Medicine and Dentistry
Ganglioglioma
100%
Glioblastoma
88%
Neoplasm
44%
Surgery
37%
Pediatrics
30%
Overall Survival
28%
Pilocytic Astrocytoma
27%
Cysteine Rich Protein 61
27%
Prognostic Factor
26%
DNA Methylation
22%
Malignant Neoplasm
21%
Brain Tumor
19%
Magnetic Resonance Imaging
18%
Biological Marker
17%
Integrin
17%
Tumor Cell
17%
Cilengitide
16%
Progression Free Survival
15%
Methylation
15%
In Vitro
14%
Tumor Progression
13%
Tumor Microenvironment
13%
Medulloblastoma
13%
Adenoviridae
13%
Factor XIII
13%
Hyponatremia
13%
Germline Mutation
13%
Artery Anastomosis
13%
Macrophage
13%
Postoperative Complication
13%
Gene Expression System
13%
Oncolytic Virus
13%
Craniopharyngioma
13%
Temozolomide
13%
Extracellular Matrix Protein
13%
Neurosurgery
13%
Craniospinal Irradiation
13%
Extracellular Matrix
13%
Fusion Gene
13%
MR-guided Focused Ultrasound
13%
Bevacizumab
13%
Elderly Patient
13%
Antiangiogenic Activity
13%
Neuro-Oncology
13%
Gene Therapy
13%
Neuropil
13%
Anterior Cerebral Artery
13%
Pituitary Adenoma
13%
Azygos
13%
Middle Meningeal Artery
13%
Keyphrases
Cysteine-rich Protein 61
15%
Postoperative Hyponatremia
13%
Fibroblast Growth Factor 13
13%
Danio Rerio
13%
RNA Interference Screen
13%
Glioneuronal Tumor
13%
Diffuse High-grade Gliomas
13%
Invasion Phenotype
13%
Neurosurgical Patients
13%
Cilengitide
13%
Pediatric Glioma
13%
Germline mutation
13%
Integrin Antagonist
13%
Glioneuronal Tumor with Neuropil-like Islands
13%
Ad-SGE-REIC
13%
Magnetic Resonance-guided Focused Ultrasound (MRgFUS)
13%
Whole Brain Radiation Therapy
13%
Extracellular Matrix
13%
Glioma
13%
Massive Epistaxis
13%
Drug Target
13%
GBM Cells
13%
Azygos Anterior Cerebral Artery
13%
Endoscopic Endonasal Transsphenoidal Surgery
13%
Malignant Glioneuronal Tumors
13%
CCN1
13%
Glioblastoma
13%
Brain Spatula
13%
Entrectinib
13%
Adhesion Molecules
13%
Poor Prognosis
13%
Transcranial Surgery
13%
Three-dimensional Exoscope
13%
H3 G34-mutant
13%
Data Review
13%
Diffuse Hemispheric Glioma
13%
Tectal Glioma
13%
Follicular Helper Cells
13%
DLGNT
10%
Evoked Potential Monitoring
9%
SLC-0111
7%
Angiogenesis
6%
Neurotrophic Tyrosine Kinase Receptor
6%
Surgery Cancellation
6%
Endonasal Transsphenoidal Surgery
6%
GBM Stem-like Cells
6%
Hypothalamic Damage
6%
Endoscopic Neurosurgery
5%
Dysgerminoma
5%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
40%
Cysteine Rich Protein 61
27%
Integrin
27%
Cilengitide
21%
Overall Survival
19%
Neoplasm
17%
Bevacizumab
16%
Hypoxia
15%
Medulloblastoma
13%
Cell Adhesion Molecule
13%
Adenoviridae
13%
Hypoxia Inducible Factor 1
13%
Cyclophosphamide
13%
Oncolytic Virus
13%
Pilocytic Astrocytoma
13%
Vincristine
13%
Doxorubicin
13%
Neurotoxicity
13%
Prednisolone
13%
Biological Marker
13%
Primary Central Nervous System Lymphoma
13%
Methotrexate
13%
Entrectinib
13%
Histone Deacetylase
13%
Pontine Glioma
13%
Carbonate Dehydratase IX
13%
Combination Therapy
10%
Hypoxia Inducible Factor
9%
Malignant Neoplasm
9%
Mouse
8%
Recurrence Free Survival
6%
Clinical Trial
5%